%0 Journal Article
%A Dorman, Klara
%A Breitenwieser, Kilian
%A Fischer, Laura
%A Zhang, Danmei
%A Probst, Victoria
%A Weiss, Lena
%A Heinrich, Kathrin
%A Kunz, Wolfgang G
%A Holch, Julian W
%A Gießen-Jung, Clemens
%A Haas, Michael
%A Boeck, Stefan
%A von Bergwelt-Baildon, Michael
%A Landfarth, Timotheus
%A Hornung, Roman
%A Casuscelli, Jozefina
%A Berger-Thürmel, Karin
%A Heinemann, Volker
%A Westphalen, C. Benedikt
%A Reischer, Anna
%T Real-world analysis of immune checkpoint inhibitor efficacy and response predictors in patients treated at the CCCMunichLMU outpatient clinic.
%J Scientific reports
%V 15
%N 1
%@ 2045-2322
%C [London]
%I Springer Nature
%M DKFZ-2025-02876
%P 43269
%D 2025
%X Prediction of response to checkpoint inhibition (ICI) and immune related adverse events (irAEs) remain a challenge in the immunotherapy of solid tumors. To better understand the real-world clinical courses under ICI and identify possible predictive markers for response and irAEs, we retrospectively collected and analysed data from our interdisciplinary CCCMunichLMU outpatient clinic. We analysed the clinical course, standard laboratory parameters and staging results of 342 patients who received ICI therapy in the interdisciplinary outpatient clinic of the CCCMunichLMU between January 2015 and November 2020. Initial response to ICI was defined as complete response, partial response, stable disease or mixed response with treatment continuation in the second radiologic staging after start of therapy. Median age of the included patients was 67 years (25-89). More male patients received ICI on our outpatient ward than female patients (67.8
%K Humans
%K Male
%K Female
%K Immune Checkpoint Inhibitors: therapeutic use
%K Immune Checkpoint Inhibitors: adverse effects
%K Aged
%K Middle Aged
%K Aged, 80 and over
%K Adult
%K Retrospective Studies
%K Neoplasms: drug therapy
%K Neoplasms: immunology
%K Treatment Outcome
%K Ambulatory Care Facilities
%K Adverse events (Other)
%K Autoimmune disorders (Other)
%K Immune checkpoint inhibitors (Other)
%K Immunotherapy (Other)
%K Response predictors (Other)
%K Solid tumors (Other)
%K Immune Checkpoint Inhibitors (NLM Chemicals)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:41361351
%2 pmc:PMC12686437
%R 10.1038/s41598-025-30220-0
%U https://inrepo02.dkfz.de/record/306901